Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 187004
Drug: metformin

First Posted Date: 2014-04-10

Last Posted Date: 2016-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02109679

Locations: 🇩🇪
1307.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 10 mg Empagliflozin/1000 mg Metformin XR
Drug: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR
Drug: 1 tablet Empagliflozin/2 tablets Metformin XR
Drug: 2 tablets 5 mg Empagliflozin/750 Metformin XR

First Posted Date: 2014-04-08

Last Posted Date: 2017-03-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT02106923

Locations: 🇺🇸
Boehringer Ingelheim Investigational Site, Austin, Texas, United States

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1181181 low dose
Drug: BI 1181181 high dose
Drug: Placebo

First Posted Date: 2014-04-08

Last Posted Date: 2014-07-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02106247

Locations: 🇧🇪
1344.20.32001 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Phase 3

Completed

Conditions: Hemorrhage

Interventions: Drug: idarucizumab

First Posted Date: 2014-04-07

Last Posted Date: 2018-01-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 503

Registration Number: NCT02104947

Locations: 🇺🇸
IU Health Methodist Hospital, Indianapolis, Indiana, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 173 locations

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 12.5 mg empagliflozin
Drug: 5 mg empagliflozin
Drug: 5 mg empagliflozin/850 mg metformin FDC
Drug: 5 mg empagliflozin/500 mg metformin FDC
Drug: 12.5 mg empagliflozin/500 mg metformin FDC
Drug: 500 mg metformin
Drug: 12.5 mg empagliflozin/850 mg metformin FDC
Drug: 850 mg metformin

First Posted Date: 2014-04-03

Last Posted Date: 2015-09-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02102932

Locations: 🇨🇳
1276.23.86002 Boehringer Ingelheim Investigational Site, Beijing, China

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2014-03-26

Last Posted Date: 2017-02-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 115397

Registration Number: NCT02096731

Locations: 🇨🇦
Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada

Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Catapres-TTS-1

First Posted Date: 2014-03-26

Last Posted Date: 2015-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02096744

Locations: 🇺🇸
253.2486.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States

Afatinib in Subjects With Kidney Dysfunction

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Afatinib moderate renally impaired
Drug: Afatinib severe renally impaired
Drug: Afatinib healthy

First Posted Date: 2014-03-26

Last Posted Date: 2016-01-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02096718

Locations: 🇩🇪
1200.216.1 Boehringer Ingelheim Investigational Site, Kiel, Germany

To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to BI 416970
Drug: BI 416970

First Posted Date: 2014-03-21

Last Posted Date: 2016-03-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02093819

Locations: 🇩🇪
1345.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain

Phase 1

Completed

Conditions: Pain, Postoperative

Interventions: Drug: BI 1026706
Drug: Placebo to BI 1026706 solution
Drug: Celecoxib
Drug: Placebo to BI 1026706 tablet

First Posted Date: 2014-03-12

Last Posted Date: 2019-04-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT02084511

Locations: 🇮🇹
1320.13.39001 Boehringer Ingelheim Investigational Site, Verona, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy